Detection and therapeutic implications of c-Met mutations in small cell lung cancer and neuroendocrine tumors

Current Pharmaceutical Design

Volumn 19, Issue 5, 2013, Pages 833-840

  Voortman, J ^a,d   Harada, T ^a,e   Chang, R P ^a,f   Killian, J K ^a   Suuriniemi, M ^a,g   Smith, W I ^b   Meltzer, P S ^a   Lucchi, M ^c   Wang, Y ^a   Giaccone, G ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b SUBURBAN HOSPITAL   (United States)

^c UNIVERSITY OF PISA   (Italy)

^d VU UNIVERSITY MEDICAL CENTER   (Netherlands)

^e KYUSHU UNIVERSITY   (Japan)

^f HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

^g DANA FARBER CANCER INSTITUTE   (United States)

Author keywords

c Met; Mutation; Neuroendocrine tumor; Tyrosine kinase inhibitor

Indexed keywords

BMS 777607; N (3 CHLOROPHENYL) 3 [3,5 DIMETHYL 4 (4 METHYL 1 PIPERAZINYLCARBONYL) 1H PYRROL 2 YLMETHYLENE] 2,3 DIHYDRO N METHYL 2 OXO 1H INDOLE 5 SULFONAMIDE; PROTEIN TYROSINE KINASE INHIBITOR; SCATTER FACTOR RECEPTOR; UNCLASSIFIED DRUG;

ARTICLE; CANCER DIAGNOSIS; CATALYSIS; COMPARATIVE GENOMIC HYBRIDIZATION; GENE MUTATION; GENE SEQUENCE; HETEROZYGOSITY; HUMAN; HUMAN TISSUE; IN VITRO STUDY; LUNG SMALL CELL CANCER; MISSENSE MUTATION; NEUROENDOCRINE TUMOR; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SITE DIRECTED MUTAGENESIS; WILD TYPE;

EID: 84876736163     PISSN: 13816128     EISSN: 18734286     Source Type: Journal    
DOI: 10.2174/138161213804547196     Document Type: Article

References (36)

1. Giaccone G, Rodriguez JA. EGFR inhibitors: what have we learned from the treatment of lung cancer? Nat Clin Pract Oncol 2005; 2: 554-61.
2. Ronsin C, Muscatelli F, Mattei MG, Breathnach R. A novel putative receptor protein tyrosine kinase of the met family. Oncogene 1993; 8: 1195-202.
3. Gonzatti-Haces M, Seth A, Park M, Copeland T, Oroszlan S, Vande Woude GF. Characterization of the TPR-MET oncogene p65 and the MET protooncogene p140 protein-tyrosine kinases. Proc Natl Acad Sci USA 1988; 85: 21-5.
4. Trusolino L, Bertotti A, Comoglio PM. MET signalling: principles and functions in development, organ regeneration and cancer. Nat Rev Mol Cell Biol 2010; 11: 834-48.
5. Tsao MS, Zhu H, Giaid A, Viallet J, Nakamura T, Park M. Hepatocyte growth factor/scatter factor is an autocrine factor for human normal bronchial epithelial and lung carcinoma cells. Cell Growth Differ 1993; 4: 571-9.
6. Rong S, Segal S, Anver M, Resau JH, Vande Woude GF. Invasiveness and metastasis of NIH 3T3 cells induced by Methepatocyte growth factor/scatter factor autocrine stimulation. Proc Natl Acad Sci USA 1994; 91: 4731-5.
7. Kubo T, Yamamoto H, Lockwood WW, et al. MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors. Int J Cancer 2009; 124: 1778-84.
8. Jo M, Stolz DB, Esplen JE, Dorko K, Michalopoulos GK, Strom SC. Cross-talk between epidermal growth factor receptor and c-Met signal pathways in transformed cells. J Biol Chem 2000; 275: 8806-11.
9. Bean J, Brennan C, Shih JY, et al. MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib. Proc Natl Acad Sci USA 2007; 104: 20932-7.
10. Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling. Science 2007; 316: 1039-43.
11. Comoglio PM, Giordano S, Trusolino L. Drug development of MET inhibitors: targeting oncogene addiction and expedience. Nat Rev Drug Discov 2008; 7: 504-16.
12. Gherardi E, Birchmeier W, Birchmeier C, Vande WG. Targeting MET in cancer: rationale and progress. Nat Rev Cancer 2012; 12: 89-103.
13. Sattler M, Reddy MM, Hasina R, Gangadhar T, Salgia R. The role of the c-Met pathway in lung cancer and the potential for targeted therapy. Ther Adv Med Oncol 2011; 3: 171-84.
14. Jeffers M, Schmidt L, Nakaigawa N, et al. Activating mutations for the met tyrosine kinase receptor in human cancer. Proc Natl Acad Sci USA 1997; 94: 11445-50.
15. Schmidt L, Duh FM, Chen F, et al. Germline and somatic mutations in the tyrosine kinase domain of the MET protooncogene in papillary renal carcinomas. Nat Genet 1997; 16: 68-73.
16. Ma PC, Kijima T, Maulik G, et al. c-MET mutational analysis in small cell lung cancer: novel juxtamembrane domain mutations regulating cytoskeletal functions. Cancer Res 2003; 63: 6272-81.
17. Aguirre de I, Salvatierra A, Font A, et al. c-Met mutational analysis in the sema and juxtamembrane domains in small-cell-lung-cancer. Translational Oncogenomics 2006; 1: 11-8.
18. Peschard P, Ishiyama N, Lin T, Lipkowitz S, Park M. A conserved DpYR motif in the juxtamembrane domain of the Met receptor family forms an atypical c-Cbl/Cbl-b tyrosine kinase binding domain binding site required for suppression of oncogenic activation. J Biol Chem 2004; 279: 29565-71.
19. Kong-Beltran M, Seshagiri S, Zha J, et al. Somatic mutations lead to an oncogenic deletion of met in lung cancer. Cancer Res 2006; 66: 283-9.
20. Lee CC, Yamada KM. Alternatively Spliced Juxtamembrane Domain of a Tyrosine Kinase Receptor Is a Multifunctional Regulatory Site. Journal of Biological Chemistry 1995; 270: 507-10.
21. Tyner JW, Fletcher LB, Wang EQ, et al. MET receptor sequence variants R970C and T992I lack transforming capacity. Cancer Res 2010; 70: 6233-7.
22. Voortman J, Lee JH, Killian JK, et al. Array comparative genomic hybridization-based characterization of genetic alterations in pulmonary neuroendocrine tumors. Proc Natl Acad Sci USA 2010; 107: 13040-5.
23. Killian JK, Walker RL, Suuriniemi M, et al. Archival fine-needle aspiration cytopathology (FNAC) samples: untapped resource for clinical molecular profiling. J Mol Diagn 2010; 12: 739-45.
24. Harada T, Lopez-Chavez A, Xi L, Raffeld M, Wang Y, Giaccone G. Characterization of epidermal growth factor receptor mutations in non-small-cell lung cancer patients of African-American ancestry. Oncogene 2011; 30: 1744-52.
25. de Gunst MM, Gallegos-Ruiz MI, Giaccone G, Rodriguez JA. Functional analysis of cancer-associated EGFR mutants using a cellular assay with YFP-tagged EGFR intracellular domain. Mol Cancer 2007; 6: 56.
26. Krishnaswamy S, Kanteti R, Duke-Cohan JS, et al. Ethnic differences and functional analysis of MET mutations in lung cancer. Clin Cancer Res 2009; 15: 5714-23.
27. Zhen Z, Giordano S, Longati P, Medico E, Campiglio M, Comoglio PM. Structural and functional domains critical for constitutive activation of the HGF-receptor (Met). Oncogene 1994; 9: 1691-7.
28. Schroeder GM, An Y, Cai ZW, et al. Discovery of N-(4-(2-Amino-3-chloropyridin-4-yloxy)-3-fluorophenyl)-4-ethoxy-1-(4-fluorophenyl)-2-oxo-1,2-dihydropyridine-3-carboxamide (BMS-777607), a Selective and Orally Efficacious Inhibitor of the Met Kinase Superfamily. J Med Chem 2009; 52: 1251-4.
29. Dai Y, Siemann DW. BMS-777607, a Small-Molecule Met Kinase Inhibitor, Suppresses Hepatocyte Growth FactorIIÇôStimulated Prostate Cancer Metastatic Phenotype In vitro. Molecular Cancer Therapeutics 2010; 9: 1554-61.
30. Catenacci DV, Cervantes G, Yala S, et al. RON (MST1R) is a novel prognostic marker and therapeutic target for gastroesophageal adenocarcinoma. Cancer Biol Ther 2011; 12: 9-46.
31. Liao AT, McMahon M, London CA. Identification of a novel germline MET mutation in dogs. Anim Genet 2006; 37: 248-52.
32. Campbell DB, Sutcliffe JS, Ebert PJ, et al. A genetic variant that disrupts MET transcription is associated with autism. Proc Natl Acad Sci USA 2006; 103: 16834-9.
33. Lee JH, Han SU, Cho H, et al. A novel germ line juxtamembrane Met mutation in human gastric cancer. Oncogene 2000; 19: 4947-53.
34. Zaffaroni D, Spinola M, Galvan A, et al. Met proto-oncogene juxtamembrane rare variations in mouse and humans: differential effects of Arg and Cys alleles on mouse lung tumorigenesis. Oncogene 2005; 24: 1084-90.
35. Jagadeeswaran R, Jagadeeswaran S, Bindokas VP, Salgia R. Activation of HGF/c-Met pathway contributes to the reactive oxygen species generation and motility of small cell lung cancer cells. Am J Physiol Lung Cell Mol Physiol 2007; 292: L1488-L1494.
36. Weidner KM, Sachs M, Riethmacher D, Birchmeier W. Mutation of juxtamembrane tyrosine residue 1001 suppresses loss-offunction mutations of the met receptor in epithelial cells. Proc Natl Acad Sci USA 1995; 92: 2597-601.